Referencia de dosis según estudios

All quantified doses in the listed studies are preclinical (rat 0.5 mg/kg/day oral, rabbit 0.25 mg/knee intra-articular); two mouse studies gave no per-kg dose, and the human obesity trials mentioned (oral 0.25 to 30 mg/day) were negative, discontinued, and not PubMed-indexed, so there is no established human protocol.

Reference only, not a recommendation: every numeric dose in the listed studies is animal (almost all rat) and spans many orders of magnitude (10 pg/kg to 2 mg/kg across efficacy and safety models); there is no established or approved human dosing protocol.

Doses shown are those used in published studies for reference only, not a recommendation; cagrilintide is investigational (not an approved medicine), so there is no established human protocol.

Reference only: the human figures (30 to 90 mcg/kg SC) are for CJC-1295 WITH DAC, the long-acting, albumin-conjugated form we do not sell. Our no-DAC product (Mod GRF 1-29, the short-acting form we sell) has no dedicated controlled human trial; its pharmacology is inferred from the sermorelin class. Applying the DAC trial's dose to a no-DAC vial would describe a molecule with a 5.8 to 8.1-day half-life for a product that clears in about 30 minutes. The mouse figure (flat 2 mcg per animal) is also from the DAC form. CJC-1295 has no approved or established human therapeutic dose.

Reference doses used in studies only, not a recommendation. The single human study is a small acute IV trial (6 insomniacs at 25 nmol/kg); the rest is rodent and multi-species animal work, so units differ (nmol/kg, mcg per 100 g, absolute mg) and no established human protocol exists.

All doses are preclinical: rodent (per-animal micrograms, subcutaneous) plus in-vitro cell culture, with no established or validated human dosing protocol for the tetrapeptide (the human "geroprotector" data come from Epithalamin, a different pineal extract).

All doses are preclinical (in vitro molar, ex vivo human skin, rodent topical/IP) and span orders of magnitude across incompatible bases; the only per-kg figures (0.2-20 mg/kg/day IP) are from one mouse emphysema study, two wound studies gave no quantified dose, and there is no established human dosing protocol (first human RCT only recruiting).

All doses are preclinical (pig, rat, guinea pig animal infusions plus in-vitro cell cultures); there is no published human trial or established human protocol for the LR3 analogue.

Nearly all doses are preclinical (rat and swine, per-kg); the one human trial used 0.03 mg/kg IV but missed its primary endpoint, so no approved or established human dose exists.

All doses are preclinical (mouse and cell culture) with no established human protocol, and the two clean oral per-kg doses (16 ug/kg to 2.5 mg/kg) both rely on engineered delivery vehicles since free KPV showed little oral benefit on its own.

All figures are research doses used in studies, not a recommendation: in vitro concentrations, small-rodent per-kg or per-mouse doses, and human topical wound concentrations (mg/mL) only, with no approved systemic human protocol and the one adequately powered human trial negative on its primary endpoint.

These are doses used in small, dated studies and case reports only (human SC 0.01-0.03 mg/kg, rat central ng doses, a 6 mg toxicity case); there is NO established or validated human dosing protocol, and this is reference information, never a recommendation.

Every administered MOTS-c dose is preclinical and intraperitoneal (mouse/rat, 0.5 to 15 mg/kg); the single human study administered nothing (observational serum levels only), so there is no established human protocol.

There is no established per-kg human dosing protocol for injected NAD+: the entry states clinic drip doses (250 to 1000 mg) are empirical not validated, no human study reported individual body weights so no per-kg figure exists, and human efficacy data are absent (rat only) while the stronger human evidence is for oral precursors NMN/NR, not intact injected NAD+.

All doses are trial-defined research doses (human phase 2/3 weekly 0.5 to 12 mg SC, plus a mouse 30 nmol/kg study); retatrutide is investigational and not EMA/FDA approved, so there is no established human protocol.

Trial-defined research doses (human phase 3: 5/10/15 mg once weekly SC, escalated from 2.5 mg). Tirzepatide is an approved prescription medicine in some markets; we supply it strictly as a research-grade material, not as a human protocol.

The only clean numeric dose is the animal 0.3 mg/kg (300 ug/kg); the human trials report no derivable dose and Selank has no approved human protocol outside Russia/Ukraine.

Best-quantified doses are preclinical rat studies (0.045-0.25 mg/kg intranasal or IP); the only human data is a small, old, non-randomized stroke trial giving 12-18 mg/day intranasal with no body weight, so no established or approved human protocol exists.

Unusually for this catalog, sermorelin (Geref) had an FDA-approved human protocol, and the pediatric GH-deficiency dose of 30 mcg/kg/day SC once daily is an established human dose; all figures here are doses used in studies, not a recommendation.

All doses shown are the doses used in the cited trials, not a recommendation; the pivotal human efficacy trials mostly failed their primary endpoints, and the only human approval (FDA FORZINITY, Sep 2025) is narrow to Barth syndrome, so there is no established human protocol for the longevity/cardiac/AMD uses studied here.

These are doses used in published studies (mostly mouse/rat/pig and one small human eye-drop trial), spanning several orders of magnitude across routes, not a recommendation; there is no approved or validated human systemic dosing protocol.

Unlike most research peptides, tesamorelin has a regulator-approved human dose (FDA Egrifta, 2 mg subcutaneous once daily), but every human trial was in HIV-associated fat accumulation and the per-kg figures are weight-estimates since the papers reported only BMI.

The only numeric study dose is an absolute 10 mg/day IM in two Russian human studies (no body weight reported, so mg/kg cannot be derived); the rat and in vitro doses are not recoverable, and thymalin is not an approved drug in the EU/US, so no established human protocol exists.

These are doses used in published human trials (reference only, not a recommendation); a standard 1.6 mg twice-weekly subcutaneous regimen exists for the approved drug thymalfasin/Zadaxin, though the strongest recent endpoints (sepsis, hepatitis B/C) were largely negative.